PHAXIAM Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
PHAXIAM Therapeutics has a total shareholder equity of €36.6M and total debt of €15.1M, which brings its debt-to-equity ratio to 41.3%. Its total assets and total liabilities are €65.5M and €28.9M respectively.
Key information
41.3%
Debt to equity ratio
€15.14m
Debt
Interest coverage ratio | n/a |
Cash | €25.19m |
Equity | €36.63m |
Total liabilities | €28.90m |
Total assets | €65.53m |
Recent financial health updates
Recent updates
ERYTECH receives non-compliance letter from Nasdaq
Oct 13Erytech Pharma reports 1H results
Sep 12Erytech drops plans to pursue FDA approval for leukemia therapy
Aug 24Our First Look At ERYTECH Pharma
Nov 16ERYTECH Pharma S.A. 2021 Q1 - Results - Earnings Call Presentation
May 06ERYTECH starts patient enrollment in pancreatic cancer study
Jan 14ERYTECH secures €10M in non-dilutive financing
Nov 02ERYTECH: Trials In Pancreatic Cancer
Oct 23Financial Position Analysis
Short Term Liabilities: PHXM's short term assets (€30.9M) exceed its short term liabilities (€17.4M).
Long Term Liabilities: PHXM's short term assets (€30.9M) exceed its long term liabilities (€11.5M).
Debt to Equity History and Analysis
Debt Level: PHXM has more cash than its total debt.
Reducing Debt: PHXM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHXM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PHXM has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 4.1% each year.